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These models were used to estimate values for α, β and α/β 
(figure 1). 
Higher α and α/β values are reported when repopulation was 
included in the LQ model. Adenocarcinomas, gliomas and 
other non-carcinomas appear to have an α/β < 10Gy when 
parameters were estimated using the basic LQ model. 
Regarding tumour sites, the same holds for prostate, breast 
and central nervous system tumours. 
 
 
Figure 1. Meta-regression results for α by LQ model, β by LQ 
model + histology, β by LQ model + site, α/β by LQ model + 
histology and α/β by LQ model + site (left to right, top to 
bottom). 
 
Conclusions: The generic value of α/β = 10Gy often used in 
biological modelling does not seem to be appropriate for all 
tumours. The data presented here provide estimates for 
various tumour sites and histologies, based on the current 
evidence from the available literature.  
Tumour histology and tumour site are equally good predictors 
for β and α/β. Furthermore, when selecting an LQ model for 
radiobiological modelling, it is important that the applied 
parameter values were estimated using the same type of LQ 
model. 
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Purpose/Objective: Our cooperative research project within 
the European Metrology Research Programme aims at 
correlating ion track structure characteristics with the 
biological effects of radiation and develops measurement and 
simulation techniques for determining ion track structure on 
different length scales from about 2 nm (diameter of the DNA 
double helix) to about 10 µm (diameter of the cell nucleus). 
Within this framework, we investigate methods to translate 
track-structure derived quantities onto the macroscopic scale 
with the aim of integrating them into clinical treatment 
planning systems which simulate and optimize the prescribed 
dose for each individual patient. 
Materials and Methods: For this purpose, input data were 
generated by simulations of ion tracks in liquid water using 
the Geant4 Monte Carlo toolkit with the Geant4-DNA 
processes. Protons covering a clinically relevant energy range 
were started in the middle of a water cube (2 µm side 
length). Energy transfer points were recorded with 
nanometer resolution.  
We investigated parameterizations of overall properties of 
ion track structure that do not describe the track structure of 
each single track in detail but may be used to translate the 
broad distributions of track structure parameters in 
macroscopic volumes to biologically relevant mean values. 
One of these parameterizations links the energy of the 
projectile to the ionization pattern of the track using the 
distances to the 10 next neighbouring ionizations while 
another parameterization deals with ionization cluster size 
distributions. 
In the clinical situation we have to deal with a mixed 
radiation field where particles of various energies hit a voxel 
from several directions. In order to find macroscopic relevant 
mean values for this scenario, it is necessary to determine 
appropriate weighting methods for the identified 
parameterizations. 
Results: We show that a dose weighted mean value of the 
mentioned track structure properties is capable of describing 
the overall track structure in a cell exposed to a mixed 
radiation field. We also investigated the macroscopic 
scenario in which several cells in a voxel are exposed to a 
mixed radiation field. For doses typically present in a 
planning target volume we can provide a relevant mean value 
without undertaking detailed simulations. 
Conclusions: The parameterizations and appropriate 
weighting methods show a way how nanometric track 
structure properties could be integrated into a treatment 
planning system without the need to perform time consuming 
simulations on the nanometer level.  
This work was funded by an EMRP Researcher Excellence 
Grant. The EMRP is jointly funded by the EMRP participating 
countries within EURAMET and the European Union. 
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Purpose/Objective: The wide variety of complex modern 
radiotherapy techniques leads to a high degree of variability 
in the dose delivered to organs outside the primary 
treatment field. For example, non-coplanar, conformal 
accelerated partial breast irradiation (APBI) and simultaneous 
integrated boost (SIB) using intensity modulation give very 
different organ doses to standard whole breast radiotherapy. 
Planning systems calculate and display dose within the region 
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of a planning scan. There is no tool describing doses outside 
this region or relating all calculated doses to radiosensitive 
organs to long-term adverse effects e.g. second cancer 
induction and/or cardiac events.  
We have developed a new software program called aRRESt 
(Radiotherapy Risk Evaluation System) which provides an 
interactive 3D visualisation of second cancer and cardiac risks 
in out-of-field organs. It can be used to compare classes of 
treatment plan and aid decision-making. The ultimate aim is 
to provide individualised risk profiles on a per-patient basis. 
Materials and Methods: A cross-platform graphical user 
interface (GUI) was developed using the Python programming 
language, with 3D visualisation and interaction provided by 
the Visualisation Tool Kit (VTK) module. The GUI provides an 
indication of lifetime attributable risk (LAR) of second cancer 
induction using the BEIR VII risk model [1], and the total risk 
of major coronary events caused by excess heart dose from 
Darby et al [2]. 
The program works by extracting the dose cube and outlined 
regions of interest (ROI) from DICOM files exported from a 
commercial treatment planning system. Mean organ doses are 
calculated from this data, and are used to estimate the 
LAR/cardiac risk.  
Results: The program has been tested on treatment plans 
extracted from the Philips Pinnacle treatment planning 
system. These plans were based on a full body CT scan of the 
anthropomorphic Rando phantom, with approximate organ 
positions outlined by an expert practitioner. Meaningful 
differences between plan types were clearly visible (see Fig. 
1). Initial feedback from clinicians was positive. 
 
 
 
Figure 1: Top: LAR risk profiles for SIB and APBI left breast 
treatment plans delivered at an age of 60 years. Left breast, 
contralateral lung and bladder second cancer risks are shown, 
alongside risk of a major coronary event. Bottom: 3D 
interactive visualisation of ROIs outlined on a CT scan of the 
Rando phantom, extracted from the Pinnacle treatment 
planning system.  
 
Conclusions: The aRRESt program provides a quick and 
convenient method of visualising the risks of second cancer 
induction between different radiotherapy treatment 
deliveries. The underlying uncertainties in the risk models 
used are large, but as more data is accumulated and a better 
understanding of radiobiology is obtained, more sophisticated 
risk models can easily be incorporated into the software. 
References: 
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Purpose/Objective: The incidence of lower third 
oesophageal tumours are increasing in most Western 
populations (1) and it is becoming increasingly clear that 
chemo-radiotherapy (CRT) is now a viable alternative to 
surgical resection in the treatment of both oesophageal and 
gastroesophageal junction (GEJ) cancer (2). With the role of 
radiotherapy dose escalation being identified as a research 
priority in improving outcomes (3), it is important to quantify 
the increased toxicity that this may pose to sites such as the 
lower oesophagus that have vital adjacent organs that up to 
now may not have been taken into consideration. This study 
therefore aims to investigate the feasibility of lower 
oesophageal dose escalation with a focus on stomach tissue 
toxicity. 
Materials and Methods: 10 patients from the SCOPE 1 
database classified as having with tumours in the lower 
region were selected at random. The original 3D conformal 
treatment plan (503D) was available for review and was 
compared to two RapidArc plans created retrospectively to 
represent the treatment arms of the forthcoming SCOPE 2 
trial: RA50 and RA60 (PTV 50Gy with a simultaneously 
integrated boost of 60Gy to PTV2). The stomach was 
contoured as both whole organ and stomach wall and dose 
constraints set according to QUANTEC (4). 
Plans were compared using dose metrics and radiobiological 
modelling of TCP was performed using the model by Geh et al 
(5). Normal tissue complication probability (NTCP) was 
